A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.
"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer (CRPC) patients," explained the lead author of the study, Dr. Otakar ?apoun, of the Department of Urology at General Teaching Hospital Charles University in Prague, Czech Republic.
"The goal of this study is to assess the possibility of the individualisation of castration-resistant prostate cancer management. In cases with no favourable change in CTC detection during chemotherapy, the early switching to another therapy should be considered," commented ?apoun on the implications of the study, which was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic.
Protocol of the grant project included the collection of peripheral blood from patients with metastatic CRPC prior to docetaxel therapy and after the fourth cycle of chemotherapy (CTX). Circulating tumour cells were detected by using a method of immunomagnetic separation. In the course of the study multiplex-PCR was performed after cytolysis of CTC and the expression of tumour-associated antigens (PSA, PSMA and EGFR) was quantified.
The methodology of the study was based on verbal evaluation together with a report of the absolute values (ng/ml). The authors recorded the levels of serum PSA (sPSA) and the fragments of respective antigens before and in the course of CTX and compared the values. They also evaluated the correlation between the change of sPSA and expression of CTC antigens during CTX.
The study included 26 patients with both samples taken in 17 of them. Median age was 72 years (54-82), mean sPSA level before and after CTX was 197.6 and 120.1ng/ml, respectively. Before CTX only 2 out of 26 patients were considered CTC negative, whereas during the CTX the CTC negativity was confirmed in 9 out of 17 cases. Before CTX, positive detection of fragments of antigens for PSA, PSMA and EGFR was confirmed in 23, 16 and 2 patients, respectively, and during CTX in 8, 3 and 1 case, respectively. The sPSA level before CTX was associated with the level of fragments for PSA (p=0.0020) and PSMA (p=00.0147). During CTX the association was seen in all antigens. However neither a change in sPSA level nor a change in positive versus negative CTC statement correlated with a change of any of the tested antigens.
The study concludes that the sPSA level has the most accurate correlation with the level of gene fragment for PSA in CTC. A favourable change in CTC quantity will occur in more than a half of patients during chemotherapy, however the change in CTC detection does not correlate with the change of the sPSA level.
"This research project is divided into several arms, among others, we are investigating the feasibility of CTC cultivation and genetic profiling," commented ?apoun referring to the possibility of follow-up research.
"This gene profile will be compared with primary tumour at the time of diagnosis. In the future, this CTC profiling might be useful for even more accurate and better tailored selection of treatment for castration-resistant prostate cancer."
Explore further: New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
More information: Reference: ?apoun O., et al. Prostate-specific antigen level and detection of circulating tumour cells in castration-resistant prostate cancer, Abstract C163, EAU 13th Central European Meeting.
Medical Xpress on facebook
Related Stories
New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
Nov 07, 2012
Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen. Patients with advanced, hormone-refractory ...
Strong evidence supports prognostic value of circulating tumor cells in breast cancer
May 05, 2011
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer
Sep 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
Japanese P2 study shows potential of combined vaccine and steroid drug in castration resistant PCa
Mar 15, 2013
Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.
Cancer cells in blood can identify risk of recurrence in breast cancer
Sep 24, 2007
Cancer cells circulating in the blood, or circulating tumour cells (CTCs), are known to be associated with a bad prognosis in women with metastatic breast cancer. Now, for the first time, a group of scientists have shown ...
Recommended for you
New role for DNA unraveler in preventing brain tumours and other cancers
3 hours ago
(Medical Xpress)—A molecule originally implicated in DNA repair may also be a crucial factor in preventing tumours such as medulloblastoma, a type of childhood brain tumour, according to research published ...
New study changes view about the genetics of leukemia risk
3 hours ago
(Medical Xpress)—A gene that helps keep blood free of cancer is controlled by tiny pieces of RNA, a finding that may lead to better ways to diagnose blood cancers and even lead to new forms of treatment, ...
Steady rise in thyroid cancer not explained by better screening, study says
18 hours ago
(HealthDay)—Better detection alone doesn't explain the dramatic increase in thyroid cancer cases seen in the United States over the past three decades, a new study says.
Breast cancer patients have unrelated plastic surgery after reconstruction
20 hours ago
(HealthDay)—Some breast cancer patients who've had breast reconstruction after mastectomy also undergo cosmetic surgery in an effort to further boost their self-image and self-esteem, according to a new ...
The Cancer Genome Atlas exposes more secrets of lethal brain tumor
23 hours ago
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
A genetic variation that could protect skin from sun damage fuels testicular cancer
23 hours ago
A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exe ...
User comments
© Medical Xpress 2011-2013, Phys.org network
A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.
"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer (CRPC) patients," explained the lead author of the study, Dr. Otakar ?apoun, of the Department of Urology at General Teaching Hospital Charles University in Prague, Czech Republic.
"The goal of this study is to assess the possibility of the individualisation of castration-resistant prostate cancer management. In cases with no favourable change in CTC detection during chemotherapy, the early switching to another therapy should be considered," commented ?apoun on the implications of the study, which was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic.
Protocol of the grant project included the collection of peripheral blood from patients with metastatic CRPC prior to docetaxel therapy and after the fourth cycle of chemotherapy (CTX). Circulating tumour cells were detected by using a method of immunomagnetic separation. In the course of the study multiplex-PCR was performed after cytolysis of CTC and the expression of tumour-associated antigens (PSA, PSMA and EGFR) was quantified.
The methodology of the study was based on verbal evaluation together with a report of the absolute values (ng/ml). The authors recorded the levels of serum PSA (sPSA) and the fragments of respective antigens before and in the course of CTX and compared the values. They also evaluated the correlation between the change of sPSA and expression of CTC antigens during CTX.
The study included 26 patients with both samples taken in 17 of them. Median age was 72 years (54-82), mean sPSA level before and after CTX was 197.6 and 120.1ng/ml, respectively. Before CTX only 2 out of 26 patients were considered CTC negative, whereas during the CTX the CTC negativity was confirmed in 9 out of 17 cases. Before CTX, positive detection of fragments of antigens for PSA, PSMA and EGFR was confirmed in 23, 16 and 2 patients, respectively, and during CTX in 8, 3 and 1 case, respectively. The sPSA level before CTX was associated with the level of fragments for PSA (p=0.0020) and PSMA (p=00.0147). During CTX the association was seen in all antigens. However neither a change in sPSA level nor a change in positive versus negative CTC statement correlated with a change of any of the tested antigens.
The study concludes that the sPSA level has the most accurate correlation with the level of gene fragment for PSA in CTC. A favourable change in CTC quantity will occur in more than a half of patients during chemotherapy, however the change in CTC detection does not correlate with the change of the sPSA level.
"This research project is divided into several arms, among others, we are investigating the feasibility of CTC cultivation and genetic profiling," commented ?apoun referring to the possibility of follow-up research.
"This gene profile will be compared with primary tumour at the time of diagnosis. In the future, this CTC profiling might be useful for even more accurate and better tailored selection of treatment for castration-resistant prostate cancer."
Explore further: New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
More information: Reference: ?apoun O., et al. Prostate-specific antigen level and detection of circulating tumour cells in castration-resistant prostate cancer, Abstract C163, EAU 13th Central European Meeting.
Medical Xpress on facebook
Related Stories
New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
Nov 07, 2012
Few available treatment options exist once prostate cancer has spread to other parts of the body and has failed to respond to therapies that involve blocking the male hormone androgen. Patients with advanced, hormone-refractory ...
Strong evidence supports prognostic value of circulating tumor cells in breast cancer
May 05, 2011
French researchers have reported the strongest proof yet that evidence of 'circulating tumor cells' found in samples of a patient's blood is strongly linked to poor outcomes such as a short time to disease progression.
New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer
Sep 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.
Japanese P2 study shows potential of combined vaccine and steroid drug in castration resistant PCa
Mar 15, 2013
Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients.
Cancer cells in blood can identify risk of recurrence in breast cancer
Sep 24, 2007
Cancer cells circulating in the blood, or circulating tumour cells (CTCs), are known to be associated with a bad prognosis in women with metastatic breast cancer. Now, for the first time, a group of scientists have shown ...
Recommended for you
New role for DNA unraveler in preventing brain tumours and other cancers
3 hours ago
(Medical Xpress)—A molecule originally implicated in DNA repair may also be a crucial factor in preventing tumours such as medulloblastoma, a type of childhood brain tumour, according to research published ...
New study changes view about the genetics of leukemia risk
3 hours ago
(Medical Xpress)—A gene that helps keep blood free of cancer is controlled by tiny pieces of RNA, a finding that may lead to better ways to diagnose blood cancers and even lead to new forms of treatment, ...
Steady rise in thyroid cancer not explained by better screening, study says
18 hours ago
(HealthDay)—Better detection alone doesn't explain the dramatic increase in thyroid cancer cases seen in the United States over the past three decades, a new study says.
Breast cancer patients have unrelated plastic surgery after reconstruction
20 hours ago
(HealthDay)—Some breast cancer patients who've had breast reconstruction after mastectomy also undergo cosmetic surgery in an effort to further boost their self-image and self-esteem, according to a new ...
The Cancer Genome Atlas exposes more secrets of lethal brain tumor
23 hours ago
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
A genetic variation that could protect skin from sun damage fuels testicular cancer
23 hours ago
A Ludwig Cancer Research study published in Cell today identifies a common mutation that dramatically increases the risk for testicular cancer—and describes a likely molecular mechanism by which it exe ...
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment